ID   Caov-3
AC   CVCL_0201
AS   CVCL_0231
SY   CaOv-3; CaOV-3; CAOV-3; CAOV3; CaOV3; CaOv3; Caov3; CA-OV-3; CaOV3 (S)
DR   BTO; BTO:0000814
DR   CLO; CLO_0002195
DR   EFO; EFO_0002148
DR   MCCL; MCC:0000119
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-75
DR   BioGRID_ORCS_Cell_line; 338
DR   BioSample; SAMN03472624
DR   BioSample; SAMN05292465
DR   BioSample; SAMN10988200
DR   cancercelllines; CVCL_0201
DR   CCRID; 1101HUM-PUMC000339
DR   CCRID; 3101HUMSCSP570
DR   CCRID; 4201HUM-CCTCC00118
DR   CCTCC; GDC0118
DR   Cell_Model_Passport; SIDM00919
DR   ChEMBL-Cells; CHEMBL3307927
DR   ChEMBL-Targets; CHEMBL614379
DR   CLS; 300319
DR   Cosmic; 687927
DR   Cosmic; 688092
DR   Cosmic; 809114
DR   Cosmic; 844349
DR   Cosmic; 906579
DR   Cosmic; 906825
DR   Cosmic; 924149
DR   Cosmic; 949225
DR   Cosmic; 1102821
DR   Cosmic; 1139227
DR   Cosmic; 1305310
DR   Cosmic; 1312190
DR   Cosmic; 1707569
DR   Cosmic; 1709259
DR   Cosmic; 2186585
DR   Cosmic; 2301585
DR   Cosmic-CLP; 906825
DR   DepMap; ACH-000713
DR   EGA; EGAS00001000610
DR   GDSC; 906825
DR   GEO; GSM184398
DR   GEO; GSM184399
DR   GEO; GSM274705
DR   GEO; GSM313711
DR   GEO; GSM459740
DR   GEO; GSM659371
DR   GEO; GSM711712
DR   GEO; GSM784569
DR   GEO; GSM851913
DR   GEO; GSM886918
DR   GEO; GSM887984
DR   GEO; GSM1001485
DR   GEO; GSM1291130
DR   GEO; GSM1669661
DR   GEO; GSM3161712
DR   GEO; GSM3161713
DR   IARC_TP53; 1416
DR   IARC_TP53; 28485
DR   IARC_TP53; 30197
DR   IGRhCellID; CaOv3
DR   IZSLER; BS TCL 165
DR   KCB; KCB 2013041YJ
DR   LiGeA; CCLE_499
DR   LINCS_LDP; LCL-1519
DR   PharmacoDB; Caov3_182_2019
DR   PRIDE; PXD003668
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0201
DR   PubChem_Cell_line; CVCL_0201
DR   Ubigene; YC-C031
DR   Wikidata; Q54808585
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=4016745;
RX   PubMed=9698466;
RX   PubMed=10318951;
RX   PubMed=12080474;
RX   PubMed=18560578;
RX   PubMed=19926575;
RX   PubMed=20164919;
RX   PubMed=20204287;
RX   PubMed=20215515;
RX   PubMed=22328975;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27235858;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=33519462;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn31544457
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/caov-3-human-ovarian-cell-line
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-069.
CC   Population: Caucasian.
CC   Doubling time: 78 hours (PubMed=4016745); 68 hours (PubMed=25984343); ~44 hours (PBCF); 65.81 hours (GrayJW panel).
CC   HLA typing: A*26:01,69:01; B*49:01,49:01; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV001802458; Zygosity=Homozygous (PubMed=24023729; PubMed=25230021; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.29%; Native American=0.12%; East Asian, North=2.22%; East Asian, South=0%; South Asian=15.22%; European, North=11.3%; European, South=68.85% (PubMed=30894373).
CC   Misspelling: CACOV-3; Note=Occasionally.
CC   Misspelling: CaCOV3; Note=Occasionally.
CC   Misspelling: CAVO3; Note=Occasionally.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D12S391: 15,23
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 18
ST   D19S433: 14,17
ST   D21S11: 30
ST   D2S1338: 16,17
ST   D3S1358: 16
ST   D5S818: 12
ST   D6S1043: 12
ST   D7S820: 10
ST   D8S1179: 9,14
ST   FGA: 24
ST   Penta D: 12
ST   Penta E: 11,15
ST   TH01: 7
ST   TPOX: 8,10
ST   vWA: 16,18
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 47
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4016745;
RA   Buick R.N., Pullano R., Trent J.M.;
RT   "Comparative properties of five human ovarian adenocarcinoma cell
RT   lines.";
RL   Cancer Res. 45:3668-3676(1985).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=18560578; DOI=10.1371/journal.pone.0002425;
RA   Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R.,
RA   Pitteri S.J., Green A.E., Ireton R.C., Zhang Q., Wang H.,
RA   O'Briant K.C., Drescher C.W., Schummer M., McIntosh M.W.,
RA   Knudsen B.S., Hanash S.M.;
RT   "Proteomic analysis of ovarian cancer cells reveals dynamic processes
RT   of protein secretion and shedding of extra-cellular domains.";
RL   PLoS ONE 3:E2425-E2425(2008).
//
RX   PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS;
RA   DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E.,
RA   Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.;
RT   "S100A1 expression in ovarian and endometrial endometrioid carcinomas
RT   is a prognostic indicator of relapse-free survival.";
RL   Am. J. Clin. Pathol. 132:846-856(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=33519462; DOI=10.3389/fphar.2020.600994;
RA   Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.;
RT   "CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro
RT   relies on translational regulation of CSAG2.";
RL   Front. Pharmacol. 11:600994.1-600994.10(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//